Eflepedocokin alfa

依来白介素 22-α

Report date: 2026/01/07 14:06:39

Base Information

Drug NameEflepedocokin alfa
Drug Alias Name注射用重组人白介素22-Fc融合蛋白Promenakin普罗纳亭F-652
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionInterleukin-22 receptor agonistsGranulocyte colony-stimulating factor replacements
TargetsInterleukin-22 receptorGranulocyte colony-stimulating factor
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Graft vs Host DiseasePancreatitis +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesEvive Biotech Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesEvive Biotech LtdNational Institute On Alcohol Abuse And AlcoholismEvive (Shanghai) Corp Ltd +[4] 
Inactive CompaniesIndiana UniversityVirginia Commonwealth University
Active IndicationsGraft vs Host DiseasePancreatitisHepatitis, Alcoholic +[6] 
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)

Other Information

ATC CodeN/A
Related LinksN/A